China SXT Pharmaceuticals (SXTC) Enterprise Value (2018 - 2025)
Historic Enterprise Value for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to -$21.2 million.
- China SXT Pharmaceuticals' Enterprise Value fell 1466.96% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.2 million, marking a year-over-year decrease of 1466.96%. This contributed to the annual value of -$18.1 million for FY2025, which is 5011.3% down from last year.
- Latest data reveals that China SXT Pharmaceuticals reported Enterprise Value of -$21.2 million as of Q3 2025, which was down 1466.96% from -$18.1 million recorded in Q1 2025.
- Over the past 5 years, China SXT Pharmaceuticals' Enterprise Value peaked at -$3.0 million during Q3 2022, and registered a low of -$31.3 billion during Q3 2021.
- Moreover, its 5-year median value for Enterprise Value was -$16.5 million (2022), whereas its average is -$3.1 billion.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 30241681.71% in 2021, then surged by 9999.05% in 2022.
- Over the past 5 years, China SXT Pharmaceuticals' Enterprise Value (Quarter) stood at -$31.3 billion in 2021, then skyrocketed by 99.99% to -$3.0 million in 2022, then crashed by 284.6% to -$11.5 million in 2023, then plummeted by 61.47% to -$18.5 million in 2024, then decreased by 14.67% to -$21.2 million in 2025.
- Its last three reported values are -$21.2 million in Q3 2025, -$18.1 million for Q1 2025, and -$18.5 million during Q3 2024.